Repositioning Candidate Details
| Candidate ID: | R0903 |
| Source ID: | DB05945 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | MDX-1303 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal toxins known as the anthrax protective antigen. |
| CAS Number: | 915947-57-8 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in anthrax exposure and bacterial infection. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | MDX-1303 targets a protein component of lethal toxins produced by the bacterium known as the anthrax protective antigen. The anthrax protective antigen initiates the onset of the illness by attaching to cells in the infected person, and then facilitates the entry of additional destructive toxins into the cells. MDX-1303 is designed to target anthrax protective antigen and protect the cells from damage by the anthrax toxins. |
| Targets: | Anthrax toxin receptor 2; Anthrax toxin receptor 1 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|